The road from discovery to clinic: Adiponectin as a biomarker of metabolic status

Research output: Contribution to journalComment/debate

39 Scopus citations

Abstract

Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists.

Original languageEnglish (US)
Pages (from-to)592-595
Number of pages4
JournalClinical pharmacology and therapeutics
Volume86
Issue number6
DOIs
StatePublished - Nov 27 2009

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The road from discovery to clinic: Adiponectin as a biomarker of metabolic status'. Together they form a unique fingerprint.

  • Cite this